Clinical trials: Therapy-related Toxicity
Toxicity, Drug, Adverse Drug Event
TIL and Anti-PD1 in Metastatic Melanoma
The ACTME study is an investigator initiated, single center phase I/II clinical trial for patients with progressive unresectable stage III or stage IV melanoma.
- Conditions
- Toxicity, Drug, Adverse Drug Event, Effects of Immunotherapy
- Trial name
- ACTME (NCT03638375)
- Testing
- Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha
- Where
- Netherlands
- Volunteers
- 34 people
- Sponsor
- Leiden University
Breast Cancer, Cardiac Toxicity
Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
RATIONALE: Studying samples of blood and tissue in the laboratory from women receiving doxorubicin and trastuzumab for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers for…
- Conditions
- Breast Cancer, Cardiac Toxicity, Cardiovascular Complications
- Trial name
- PACE in BC (NCT00875238)
- Testing
- trastuzumab, doxorubicin hydrochloride, polymorphism analysis
- Where
- 4 sites in United States
- Volunteers
- 133 people
- Sponsor
- Vanderbilt University
Stage III Melanoma
Interferon Toxicities in Melanoma Treatment
The primary objective of this study is to quantify and compare the prevalence of adverse events (AEs) in patients with stage III melanoma before and after initiation of interferon (IFN) therapy in a real-world setting.
- Trial name
- ITMT (NCT02794636)
- Volunteers
- 436 people
- Sponsor
- Bristol-Myers Squibb
Chemotherapeutic Agent Toxicity, Pain
Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel
RATIONALE: Cryotherapy may help prevent peripheral neuropathy or nail toxicity in patients receiving chemotherapy. PURPOSE: This clinical trial studies cryotherapy in preventing peripheral neuropathy and nail toxicity in patients…
- Conditions
- Chemotherapeutic Agent Toxicity, Pain, Peripheral Neuropathy, Recurrent Breast Cancer
- Trial name
- NCT01243541
- Testing
- cryotherapy, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Northwestern University
Cardiac Toxicity, Leukemia
Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Cardiac Toxicity, Leukemia, Lymphoma
- Trial name
- T-Cell #4 (NCT01230983)
- Testing
- asparaginase, cytarabine, dexrazoxane hydrochloride
- Volunteers
- 573 people
- Sponsor
- Children's Oncology Group
Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia
- Trial name
- NCT00074165
- Testing
- Rituxan, Cyclophosphamide, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- OHSU Knight Cancer Institute
Colorectal Cancer, Dermatologic Complications
S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride
RATIONALE: Questionnaires that patients can use to assess skin toxicities related to treatment may help identify the intermediate-and long-term effects of cetuximab, panitumumab, or erlotinib hydrochloride.
- Conditions
- Colorectal Cancer, Dermatologic Complications, Lung Cancer, Therapy-related Toxicity
- Trial name
- NCT01416688
- Testing
- assessment of therapy complications, psychosocial assessment and care, quality-of-life assessment
- Where
- 113 sites in United States
- Volunteers
- 146 people
- Sponsor
- SWOG Cancer Research Network
Methanol Poisoning, Toxic Optic Neuropathy
Therapy of Toxic Optic Neuropathy Via Combination of Stem Cells With Electromagnetic Stimulation
The axons of the retinal ganglion cells combine to form the optic nerve. The optic nerve transmits electrical signals to the visual cortex by various synapses.
- Conditions
- Methanol Poisoning, Toxic Optic Neuropathy, Stem Cell Tyrosine Kinase 1 Y842X, Magnetic Field Exposure
- Trial name
- Magnovision (NCT04877067)
- Testing
- Wharton jelly derived mesenchymal stem cell, Repetitive electromagnetic stimulation
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 18 people
- Sponsor
- Ankara Universitesi Teknokent
Anthracycline-induced Cardiac Toxicity, Breast Cancer
Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients
This study, called "ROSUBREAST", is a multicenter, double-blind, randomized clinical trial evaluating whether rosuvastatin (20 mg daily) can protect the heart in women with breast cancer receiving anthracycline-based…
- Conditions
- Anthracycline-induced Cardiac Toxicity, Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer, Anthracycline-induced Cardiotoxicity
- Trial name
- ROSUBREAST (NCT07254221)
- Testing
- Rosuvastatin 20 mg/day
- Where
- 7 sites in Iran
- Volunteers
- 400 people
- Sponsor
- Shiraz University of Medical Sciences